Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many
patients with hematologic malignancies but >50% of this patients will develop extensive
chronic graft-versus-host disease (cGVHD), which remains the most important complication
after HTC.
Classically, the most effective strategies to prevent GVHD have not improved survival;
therefore, the new strategies are being sought.
This study is designed in two phases: the main objective for phase I study is the more
suitable dose for ixazomib search. Phase II study is designed to evaluate the efficacy of
ixazomib at the doses stablished in phase I.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla